Full Breakdown
Hims & Hers Health to Acquire Eucalyptus in $1.15 Billion Deal
2/20/2026, 11:39:33 AM
Acquisition Overview
Hims & Hers Health, a prominent telehealth platform, has announced its agreement to acquire the Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion. The acquisition aims to enhance Hims & Hers' international presence, particularly in Australia and Japan, while solidifying its foothold in existing markets such as the United Kingdom, Germany, and Canada. The transaction will involve an upfront cash payment of approximately $240 million, with the remainder consisting of deferred payments over 18 months and performance-based earnouts through early 2029.
Eucalyptus: A Strategic Addition
Founded in 2019, Eucalyptus has quickly established itself as a leader in consumer healthcare, operating popular brands like Juniper and Pilot. The company has facilitated nearly two million consultations and serves over 775,000 customers, boasting an annual revenue run-rate exceeding $450 million. Eucalyptus is recognized for its customer-first approach and has published over 20 peer-reviewed articles on healthcare outcomes. Following the acquisition, Eucalyptus CEO Tim Doyle will transition to the role of Senior Vice President of International at Hims & Hers, overseeing the company's global operations.
Financial Structure and Implications
The deal is structured to maintain Hims & Hers' financial flexibility, allowing the company to finance most of the acquisition using existing cash and future operating cash flows from its U.S. business. Hims & Hers retains the option to settle a majority of deferred and earnout payments in either cash or stock. This strategic acquisition is expected to bolster Hims & Hers' commercial relationships and create new opportunities for collaboration with biotech innovators and drug manufacturers.
Official Statements & Responses
Andrew Dudum, founder and CEO of Hims & Hers, emphasized the global demand for personalized healthcare, stating, “Healthcare challenges are global, and so is the demand for simpler, transparent, and more personalized healthcare.” He expressed confidence that the acquisition would position Hims & Hers as a leading global consumer health platform. Tim Doyle echoed this sentiment, highlighting the potential to accelerate the movement toward affordable healthcare that feels like a luxury.
Criticism & Opposition
Despite the optimistic outlook, Hims & Hers faces challenges, including a lawsuit from Novo Nordisk related to a regulatory issue that forced the company to withdraw a compounded weight-loss drug from the market. This setback has raised concerns about the company's domestic performance, making the timing of the international expansion particularly critical.
What's Next
The acquisition is expected to close in mid-2026, pending regulatory approvals and customary closing conditions. Hims & Hers plans to leverage Eucalyptus' local expertise to effectively enter new markets and enhance its service offerings globally.
Verbatim Quotes
“By joining Hims & Hers, we will help more people globally believe in the future of healthcare: simple, high-quality, personal, and designed to help prevent disease, instead of merely treating it,” — Tim Doyle, CEO of Eucalyptus.
“With Eucalyptus, we will not only enter new markets, we will expand our ability to serve customers globally, trusting local experts to be a key part of how we transform healthcare into a customer-first, personalized industry.” — Andrew Dudum, CEO of Hims & Hers.
